FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127832422> ?p ?o ?g. }

• W2127832422 endingPage "29" @default.
• W2127832422 startingPage "21" @default.
• W2127832422 abstract "Overexpression of the HER2/neu oncogene (also known as c-erbB2) is a frequent molecular event in multiple human cancers, including breast and ovarian cancer. Patients with cancer that overexpress HER2/neu are associated with unfavorable prognosis, shorter relapse time, and low survival rate. Treatments that target HER2/neu expression in cancer cells have been shown to be useful strategies to significantly reverse the malignancy induced by HER2/neu overexpression. The humanized anti-HER2/neu antibody, trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA) has proven to be effective in clinical trials in patients with metastatic breast cancer. In addition, tyrosine kinase inhibitors such as emodin can also target the HER2/neu oncogenic activity. Emodin treatment inhibits HER2/neu tyrosine kinase activity and preferentially suppresses the transformation of HER2/neu-overexpressing breast cancer cells. Emodin also sensitizes HER2/neu-overexpressing cancer cells to chemotherapeutic agents, including cisplatin, doxorubicin, etoposide, and paclitaxel. Alternatively, HER2/neu overexpression can be repressed by attenuating the promoter activity of the HER2/neu gene. We have identified a number of potent transcriptional regulators, including the ets family member PEA3 and the adenovirus type 5 E1A, which are able to repress HER2/neu gene expression. Expression of these transcriptional regulators resulted in downregulation of HER2/neu promoter activity and reversed the transformed phenotype of the cancer cells in vitro. In vivo studies show that these HER2/neu repressors can act therapeutically as tumor suppressor genes for tumors that overexpress HER2/neu. These preclinical studies clearly indicate that transcriptional repressors that downregulate HER2/neu can be effective regimens for cancer treatment in a gene therapy format. More importantly, the tumor-free survival rate of treated animals is dramatically increased under nontoxic doses compared with untreated animals. A phase I clinical trial using E1A-liposome in breast and ovarian patients has recently been completed. Following treatment, we observed downregulation of the HER2/neu protein accompanied by E1A expression in both cancer and noncancer cells. Numbers of tumor cells in the pleural effusion or ascites were found to be dramatically reduced after treatment. Furthermore, apoptosis was strongly induced in the tumor cells. A phase II study has been started to further evaluate therapeutic efficacy and tumor suppression mechanisms of E1A. These studies show the clinical potential of targeting HER2/neu in cancer therapy." @default.
• W2127832422 created "2016-06-24" @default.
• W2127832422 creator A5018617106 @default.
• W2127832422 creator A5022814889 @default.
• W2127832422 creator A5058094136 @default.
• W2127832422 creator A5076834432 @default.
• W2127832422 date "2001-12-01" @default.
• W2127832422 modified "2023-09-23" @default.
• W2127832422 title "Targeting HER2: Recent developments and future directions for breast cancer patients" @default.
• W2127832422 cites W1488828742 @default.
• W2127832422 cites W1502854409 @default.
• W2127832422 cites W1514463309 @default.
• W2127832422 cites W1520023565 @default.
• W2127832422 cites W1541544453 @default.
• W2127832422 cites W1560003193 @default.
• W2127832422 cites W1580523172 @default.
• W2127832422 cites W1631701494 @default.
• W2127832422 cites W167845783 @default.
• W2127832422 cites W1685536199 @default.
• W2127832422 cites W17219398 @default.
• W2127832422 cites W1755920412 @default.
• W2127832422 cites W1837534061 @default.
• W2127832422 cites W187705992 @default.
• W2127832422 cites W1877098097 @default.
• W2127832422 cites W1888503564 @default.
• W2127832422 cites W1903901814 @default.
• W2127832422 cites W1903921724 @default.
• W2127832422 cites W1924784781 @default.
• W2127832422 cites W1933350662 @default.
• W2127832422 cites W1966205468 @default.
• W2127832422 cites W1972536591 @default.
• W2127832422 cites W1976507335 @default.
• W2127832422 cites W1980182768 @default.
• W2127832422 cites W1983000778 @default.
• W2127832422 cites W1984363030 @default.
• W2127832422 cites W1985827132 @default.
• W2127832422 cites W1989009382 @default.
• W2127832422 cites W1990468962 @default.
• W2127832422 cites W1990725971 @default.
• W2127832422 cites W1996591735 @default.
• W2127832422 cites W1999248691 @default.
• W2127832422 cites W1999614623 @default.
• W2127832422 cites W1999828947 @default.
• W2127832422 cites W2001124278 @default.
• W2127832422 cites W2002517161 @default.
• W2127832422 cites W2009883127 @default.
• W2127832422 cites W2021326683 @default.
• W2127832422 cites W2024306318 @default.
• W2127832422 cites W2025561101 @default.
• W2127832422 cites W2026349049 @default.
• W2127832422 cites W2028387622 @default.
• W2127832422 cites W2031190564 @default.
• W2127832422 cites W2035211789 @default.
• W2127832422 cites W2035332337 @default.
• W2127832422 cites W2040142253 @default.
• W2127832422 cites W2040239567 @default.
• W2127832422 cites W2044960823 @default.
• W2127832422 cites W2050905927 @default.
• W2127832422 cites W2052016477 @default.
• W2127832422 cites W2052512448 @default.
• W2127832422 cites W2053189267 @default.
• W2127832422 cites W2058685264 @default.
• W2127832422 cites W2062713892 @default.
• W2127832422 cites W2065841267 @default.
• W2127832422 cites W2068122330 @default.
• W2127832422 cites W2070794112 @default.
• W2127832422 cites W2072140252 @default.
• W2127832422 cites W2072940000 @default.
• W2127832422 cites W2076750304 @default.
• W2127832422 cites W2082561986 @default.
• W2127832422 cites W2085665257 @default.
• W2127832422 cites W2092124718 @default.
• W2127832422 cites W2092229345 @default.
• W2127832422 cites W2095156669 @default.
• W2127832422 cites W2097767970 @default.
• W2127832422 cites W2104670195 @default.
• W2127832422 cites W2104990131 @default.
• W2127832422 cites W2106413201 @default.
• W2127832422 cites W2107386750 @default.
• W2127832422 cites W2112226781 @default.
• W2127832422 cites W2116555647 @default.
• W2127832422 cites W2117079180 @default.
• W2127832422 cites W2120479947 @default.
• W2127832422 cites W2123449896 @default.
• W2127832422 cites W2128366838 @default.
• W2127832422 cites W2137672355 @default.
• W2127832422 cites W2137980008 @default.
• W2127832422 cites W2139476145 @default.
• W2127832422 cites W2141393790 @default.
• W2127832422 cites W2147772438 @default.
• W2127832422 cites W2151605875 @default.
• W2127832422 cites W2152936136 @default.
• W2127832422 cites W2153042655 @default.
• W2127832422 cites W2154027407 @default.
• W2127832422 cites W2159291798 @default.
• W2127832422 cites W2159363679 @default.
• W2127832422 cites W2165856277 @default.
• W2127832422 cites W2170484275 @default.

• next